Variant: rs121913286 

    present in Gene: PIK3CA
    present in Chromosome: 3
    Position on Chromosome: 179218306
    Alleles of this Variant: C/A;G

rs121913286 in PIK3CA gene and Adenocarcinoma of prostate PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913286 in PIK3CA gene and Brain Neoplasms PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913286 in PIK3CA gene and Carcinoma of lung PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

rs121913286 in PIK3CA gene and Colorectal Neoplasms PMID 22162582 2012 Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials.

PMID 20453058 2010 Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.

PMID 22162589 2012 Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

PMID 15254419 2004 The PIK3CA gene is mutated with high frequency in human breast cancers.

PMID 19903786 2009 PIK3CA mutations predict local recurrences in rectal cancer patients.

PMID 19366826 2009 PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.

PMID 18725974 2008 Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.

PMID 20619739 2010 Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

PMID 15647370 2005 Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.

PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

PMID 15016963 2004 High frequency of mutations of the PIK3CA gene in human cancers.

rs121913286 in PIK3CA gene and Cutaneous Melanoma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913286 in PIK3CA gene and Gastric Adenocarcinoma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913286 in PIK3CA gene and Glioblastoma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913286 in PIK3CA gene and Malignant Uterine Corpus Neoplasm PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913286 in PIK3CA gene and Mammary Neoplasms PMID 15805248 2005 PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.

PMID 18725974 2008 Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.

PMID 22162589 2012 Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

PMID 15647370 2005 Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.

PMID 22162582 2012 Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials.

PMID 18676830 2008 An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.

PMID 20453058 2010 Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.

PMID 15254419 2004 The PIK3CA gene is mutated with high frequency in human breast cancers.

rs121913286 in PIK3CA gene and Medulloblastoma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913286 in PIK3CA gene and Squamous cell carcinoma of the head and neck PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913286 in PIK3CA gene and Transitional cell carcinoma of bladder PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913286 in PIK3CA gene and Uterine Carcinosarcoma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913286 in PIK3CA gene and Uterine Cervical Neoplasm PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913286 in PIK3CA gene and ovarian neoplasm PMID 15647370 2005 Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.

PMID 22271473 2012 PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.